{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T09:20:49Z","timestamp":1788168049373,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00108-026-02133-1","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T12:59:36Z","timestamp":1780664376000},"page":"1044-1052","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Personalisierte Arzneimitteltherapie des kolorektalen Karzinoms","Personalized pharmacotherapy of colorectal cancer"],"prefix":"10.1007","volume":"67","author":[{"given":"Nadine","family":"Schulte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"2133_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray\u00a0F, Laversanne\u00a0M, Sung\u00a0H et\u00a0al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"2133_CR2","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1136\/gutjnl-2022-327736","volume":"72","author":"E Morgan","year":"2023","unstructured":"Morgan\u00a0E, Arnold\u00a0M, Gini\u00a0A et\u00a0al (2023) Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut 72:338\u2013344. https:\/\/doi.org\/10.1136\/gutjnl-2022-327736","journal-title":"Gut"},{"key":"2133_CR3","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3322\/caac.21772","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel\u00a0RL, Wagle\u00a0NS, Cercek\u00a0A et\u00a0al (2023) Colorectal cancer statistics, 2023. CA Cancer J Clin 73:233\u2013254. https:\/\/doi.org\/10.3322\/caac.21772","journal-title":"CA Cancer J Clin"},{"key":"2133_CR4","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/0092-8674(90)90186-i","volume":"61","author":"ER Fearon","year":"1990","unstructured":"Fearon\u00a0ER, Vogelstein\u00a0B (1990) A genetic model for colorectal tumorigenesis. Cell 61:759\u2013767. https:\/\/doi.org\/10.1016\/0092-8674(90)90186-i","journal-title":"Cell"},{"key":"2133_CR5","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nature11252","volume":"487","author":"Cancer Genome Atlas N","year":"2012","unstructured":"Cancer Genome Atlas N (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330\u2013337. https:\/\/doi.org\/10.1038\/nature11252","journal-title":"Nature"},{"key":"2133_CR6","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le\u00a0DT, Uram\u00a0JN, Wang\u00a0H et\u00a0al (2015) PD\u20111 Blockade in Tumors with Mismatch-Repair Deficiency. N\u00a0Engl J Med 372:2509\u20132520. https:\/\/doi.org\/10.1056\/NEJMoa1500596","journal-title":"N Engl J Med"},{"key":"2133_CR7","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1056\/NEJMoa2504650","volume":"393","author":"A Martling","year":"2025","unstructured":"Martling\u00a0A, Hed Myrberg\u00a0I, Nilbert\u00a0M et\u00a0al (2025) Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer. N\u00a0Engl J Med 393:1051\u20131064. https:\/\/doi.org\/10.1056\/NEJMoa2504650","journal-title":"N Engl J Med"},{"key":"2133_CR8","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/nm.3967","volume":"21","author":"J Guinney","year":"2015","unstructured":"Guinney\u00a0J, Dienstmann\u00a0R, Wang\u00a0X et\u00a0al (2015) The consensus molecular subtypes of colorectal cancer. Nat Med 21:1350\u20131356. https:\/\/doi.org\/10.1038\/nm.3967","journal-title":"Nat Med"},{"key":"2133_CR9","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1016\/S0140-6736(07)61866-2","volume":"370","author":"R Gray","year":"2007","unstructured":"Quasar Collaborative G, Gray\u00a0R, Barnwell\u00a0J et\u00a0al (2007) Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370:2020\u20132029. https:\/\/doi.org\/10.1016\/S0140-6736(07)61866-2","journal-title":"Lancet"},{"key":"2133_CR10","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.annonc.2020.06.022","volume":"31","author":"G Argiles","year":"2020","unstructured":"Argiles\u00a0G, Tabernero\u00a0J, Labianca\u00a0R et\u00a0al (2020) Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 31:1291\u20131305. https:\/\/doi.org\/10.1016\/j.annonc.2020.06.022","journal-title":"Ann Oncol"},{"key":"2133_CR11","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","volume":"386","author":"J Tie","year":"2022","unstructured":"Tie\u00a0J, Cohen\u00a0JD, Lahouel\u00a0K et\u00a0al (2022) Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. N\u00a0Engl J Med 386:2261\u20132272. https:\/\/doi.org\/10.1056\/NEJMoa2200075","journal-title":"N Engl J Med"},{"key":"2133_CR12","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1056\/NEJMoa2507874","volume":"394","author":"FA Sinicrope","year":"2026","unstructured":"Sinicrope\u00a0FA, Ou\u00a0FS, Arnold\u00a0D et\u00a0al (2026) Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer. N\u00a0Engl J Med 394:1155\u20131166. https:\/\/doi.org\/10.1056\/NEJMoa2507874","journal-title":"N Engl J Med"},{"key":"2133_CR13","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","volume":"26","author":"M Chalabi","year":"2020","unstructured":"Chalabi\u00a0M, Fanchi\u00a0LF, Dijkstra\u00a0KK et\u00a0al (2020) Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med 26:566\u2013576. https:\/\/doi.org\/10.1038\/s41591-020-0805-8","journal-title":"Nat Med"},{"key":"2133_CR14","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","volume":"390","author":"M Chalabi","year":"2024","unstructured":"Chalabi\u00a0M, Verschoor\u00a0YL, Tan\u00a0PB et\u00a0al (2024) Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer. N\u00a0Engl J Med 390:1949\u20131958. https:\/\/doi.org\/10.1056\/NEJMoa2400634","journal-title":"N Engl J Med"},{"key":"2133_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","volume":"22","author":"RR Bahadoer","year":"2021","unstructured":"Bahadoer\u00a0RR, Dijkstra\u00a0EA, van Etten\u00a0B et\u00a0al (2021) Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 22:29\u201342. https:\/\/doi.org\/10.1016\/S1470-2045(20)30555-6","journal-title":"Lancet Oncol"},{"key":"2133_CR16","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1200\/JCO.23.01208","volume":"42","author":"FS Verheij","year":"2024","unstructured":"Verheij\u00a0FS, Omer\u00a0DM, Williams\u00a0H et\u00a0al (2024) Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial. J\u00a0Clin Oncol 42:500\u2013506. https:\/\/doi.org\/10.1200\/JCO.23.01208","journal-title":"J Clin Oncol"},{"key":"2133_CR17","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","volume":"386","author":"A Cercek","year":"2022","unstructured":"Cercek\u00a0A, Lumish\u00a0M, Sinopoli\u00a0J et\u00a0al (2022) PD\u20111 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. N\u00a0Engl J Med 386:2363\u20132376. https:\/\/doi.org\/10.1056\/NEJMoa2201445","journal-title":"N Engl J Med"},{"key":"2133_CR18","doi-asserted-by":"publisher","first-page":"4575","DOI":"10.1200\/JCO.2007.11.0833","volume":"25","author":"JS Tomlinson","year":"2007","unstructured":"Tomlinson\u00a0JS, Jarnagin\u00a0WR, DeMatteo\u00a0RP et\u00a0al (2007) Actual 10-year survival after resection of colorectal liver metastases defines cure. J\u00a0Clin Oncol 25:4575\u20134580. https:\/\/doi.org\/10.1200\/JCO.2007.11.0833","journal-title":"J Clin Oncol"},{"key":"2133_CR19","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1200\/JCO.2006.09.0928","volume":"25","author":"A Falcone","year":"2007","unstructured":"Falcone\u00a0A, Ricci\u00a0S, Brunetti\u00a0I et\u00a0al (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J\u00a0Clin Oncol 25:1670\u20131676. https:\/\/doi.org\/10.1200\/JCO.2006.09.0928","journal-title":"J Clin Oncol"},{"key":"2133_CR20","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1093\/annonc\/mdx119","volume":"28","author":"N Boeckx","year":"2017","unstructured":"Boeckx\u00a0N, Koukakis\u00a0R, Op de Beeck\u00a0K et\u00a0al (2017) Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies. Ann Oncol 28:1862\u20131868. https:\/\/doi.org\/10.1093\/annonc\/mdx119","journal-title":"Ann Oncol"},{"key":"2133_CR21","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1200\/JCO.2014.59.4812","volume":"33","author":"E Van Cutsem","year":"2015","unstructured":"Van Cutsem\u00a0E, Lenz\u00a0HJ, Kohne\u00a0CH et\u00a0al (2015) Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J\u00a0Clin Oncol 33:692\u2013700. https:\/\/doi.org\/10.1200\/JCO.2014.59.4812","journal-title":"J Clin Oncol"},{"key":"2133_CR22","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/S1470-2045(16)30269-8","volume":"17","author":"S Stintzing","year":"2016","unstructured":"Stintzing\u00a0S, Modest\u00a0DP, Rossius\u00a0L et\u00a0al (2016) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol 17:1426\u20131434. https:\/\/doi.org\/10.1016\/S1470-2045(16)30269-8","journal-title":"Lancet Oncol"},{"key":"2133_CR23","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1001\/jama.2017.7105","volume":"317","author":"AP Venook","year":"2017","unstructured":"Venook\u00a0AP, Niedzwiecki\u00a0D, Lenz\u00a0HJ et\u00a0al (2017) Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA 317:2392\u20132401. https:\/\/doi.org\/10.1001\/jama.2017.7105","journal-title":"JAMA"},{"key":"2133_CR24","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","volume":"28","author":"D Arnold","year":"2017","unstructured":"Arnold\u00a0D, Lueza\u00a0B, Douillard\u00a0JY et\u00a0al (2017) Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol 28:1713\u20131729. https:\/\/doi.org\/10.1093\/annonc\/mdx175","journal-title":"Ann Oncol"},{"key":"2133_CR25","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andre","year":"2020","unstructured":"Andre\u00a0T, Shiu\u00a0KK, Kim\u00a0TW et\u00a0al (2020) Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N\u00a0Engl J Med 383:2207\u20132218. https:\/\/doi.org\/10.1056\/NEJMoa2017699","journal-title":"N Engl J Med"},{"key":"2133_CR26","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0140-6736(24)02848-4","volume":"405","author":"T Andre","year":"2025","unstructured":"Andre\u00a0T, Elez\u00a0E, Lenz\u00a0HJ et\u00a0al (2025) Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial. Lancet 405:383\u2013395. https:\/\/doi.org\/10.1016\/S0140-6736(24)02848-4","journal-title":"Lancet"},{"key":"2133_CR27","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1200\/JCO.20.02088","volume":"39","author":"J Tabernero","year":"2021","unstructured":"Tabernero\u00a0J, Grothey\u00a0A, Van Cutsem\u00a0E et\u00a0al (2021) Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. J\u00a0Clin Oncol 39:273\u2013284. https:\/\/doi.org\/10.1200\/JCO.20.02088","journal-title":"J Clin Oncol"},{"key":"2133_CR28","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/s41591-024-03443-3","volume":"31","author":"S Kopetz","year":"2025","unstructured":"Kopetz\u00a0S, Yoshino\u00a0T, Van Cutsem\u00a0E et\u00a0al (2025) Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a\u00a0randomized phase\u00a03\u00a0trial. Nat Med 31:901\u2013908. https:\/\/doi.org\/10.1038\/s41591-024-03443-3","journal-title":"Nat Med"},{"key":"2133_CR29","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1158\/2159-8290.CD-11-0109","volume":"1","author":"A Bertotti","year":"2011","unstructured":"Bertotti\u00a0A, Migliardi\u00a0G, Galimi\u00a0F et\u00a0al (2011) A molecularly annotated platform of patient-derived xenografts (\u201cxenopatients\u201d) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 1:508\u2013523. https:\/\/doi.org\/10.1158\/2159-8290.CD-11-0109","journal-title":"Cancer Discov"},{"key":"2133_CR30","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","volume":"17","author":"A Sartore-Bianchi","year":"2016","unstructured":"Sartore-Bianchi\u00a0A, Trusolino\u00a0L, Martino\u00a0C et\u00a0al (2016) Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 17:738\u2013746. https:\/\/doi.org\/10.1016\/S1470-2045(16)00150-9","journal-title":"Lancet Oncol"},{"key":"2133_CR31","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/S1470-2045(23)00150-X","volume":"24","author":"JH Strickler","year":"2023","unstructured":"Strickler\u00a0JH, Cercek\u00a0A, Siena\u00a0S et\u00a0al (2023) Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol 24:496\u2013508. https:\/\/doi.org\/10.1016\/S1470-2045(23)00150-X","journal-title":"Lancet Oncol"},{"key":"2133_CR32","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S1470-2045(24)00380-2","volume":"25","author":"K Raghav","year":"2024","unstructured":"Raghav\u00a0K, Siena\u00a0S, Takashima\u00a0A et\u00a0al (2024) Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial. Lancet Oncol 25:1147\u20131162. https:\/\/doi.org\/10.1016\/S1470-2045(24)00380-2","journal-title":"Lancet Oncol"},{"key":"2133_CR33","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","volume":"383","author":"DS Hong","year":"2020","unstructured":"Hong\u00a0DS, Fakih\u00a0MG, Strickler\u00a0JH et\u00a0al (2020) KRAS(G12C) Inhibition with Sotorasib in Advanced Solid Tumors. N\u00a0Engl J Med 383:1207\u20131217. https:\/\/doi.org\/10.1056\/NEJMoa1917239","journal-title":"N Engl J Med"},{"key":"2133_CR34","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1200\/JCO.23.00434","volume":"41","author":"TS Bekaii-Saab","year":"2023","unstructured":"Bekaii-Saab\u00a0TS, Yaeger\u00a0R, Spira\u00a0AI et\u00a0al (2023) Adagrasib in Advanced Solid Tumors Harboring a KRAS(G12C) Mutation. J\u00a0Clin Oncol 41:4097\u20134106. https:\/\/doi.org\/10.1200\/JCO.23.00434","journal-title":"J Clin Oncol"},{"key":"2133_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01878-9","volume":"22","author":"A Bayle","year":"2023","unstructured":"Bayle\u00a0A, Belcaid\u00a0L, Palmieri\u00a0LJ et\u00a0al (2023) Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study. Mol Cancer 22:176. https:\/\/doi.org\/10.1186\/s12943-023-01878-9","journal-title":"Mol Cancer"},{"key":"2133_CR36","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/3425291","volume":"2019","author":"B Hou","year":"2019","unstructured":"Hou\u00a0B, Tang\u00a0Y, Li\u00a0W et\u00a0al (2019) Efficiency of CAR\u2011T Therapy for Treatment of Solid Tumor in Clinical Trials: A Meta-Analysis. Dis Markers 2019:3425291. https:\/\/doi.org\/10.1155\/2019\/3425291","journal-title":"Dis Markers"},{"key":"2133_CR37","doi-asserted-by":"crossref","unstructured":"Zhan et\u00a0al., Signal Transduct Ther. 2025 Jan 15;10(1):24","DOI":"10.1038\/s41392-024-02097-4"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-026-02133-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-026-02133-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-026-02133-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T08:49:03Z","timestamp":1788166143000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-026-02133-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2133"],"URL":"https:\/\/doi.org\/10.1007\/s00108-026-02133-1","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"11 May 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.\u00a0Schulte gibt an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}